Evidence map›Paper›PMID 30237262›Full record

Trial reportHaematologica2018

Daratumumab plus lenalidomide and dexamethasone

Meletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P Joy Ho, Kihyun Kim and 23 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05527340 (Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.), which is not on this map. Cited by 118 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 3 pooled it
24.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05527340 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

TypeinterventionalSponsorPETHEMA FoundationRan2022 to 2029Enrolled140ConditionsMultiple MyelomaArmsIberdomide, Dexamethasone, Daratumumab
3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 3 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 11 countries.

Meletios A DimopoulosThe National and Kapodistrian University of Athens, Greece mdimop@med.uoa.gr.
Jesus San-MiguelClínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain.
Andrew BelchDepartment of Oncology, University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada.
Darrell WhiteQEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.
Lotfi BenboubkerService d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France.
Gordon CookSt James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, UK.
Merav LeibaSheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
James MortonIcon Cancer Care, South Brisbane, QLD, Australia.
P Joy HoInstitute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Kihyun KimDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Naoki TakezakoDepartment of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan.
Philippe MoreauDepartment of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Jonathan L KaufmanWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Heather J SutherlandLeukemia/Bone Marrow Transplant Program, University of British Columbia, Vancouver, Canada.
Marc LalancetteCHU de Québec Research Center, Faculty of Medicine, Laval University, Canada.
Hila MagenInstitute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Jin Seok KimYonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
H Miles PrinceCabrini Hospital, Epworth HealthCare and Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia.
Tara CochraneGold Coast University Hospital, Southport, QLD, Australia.
Albert OriolInstitut Català d'Oncologia i Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona, Spain.
Nizar J BahlisUniversity of Calgary, Arnie Charbonneau Cancer Institute, Alberta, Canada.
Ajai ChariIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Lisa O'RourkeJanssen Research & Development, LLC, Spring House, PA, USA.
Kaida WuJanssen Research & Development, LLC, Spring House, PA, USA.
Jordan M SchecterJanssen Research & Development, LLC, Raritan, NJ, USA.
Tineke CasneufJanssen Research & Development, Beerse, Belgium.
Christopher ChiuJanssen Research & Development, LLC, Spring House, PA, USA.
David SoongJanssen Research & Development, LLC, Spring House, PA, USA.
A Kate SasserGenmab US, Inc, Princeton, NJ, USA.
Nushmia Z KhokharJanssen Research & Development, LLC, Spring House, PA, USA.
Hervé Avet-LoiseauUnite de Genomique du Myelome, IUC-Oncopole, Toulouse, France.
Saad Z UsmaniLevine Cancer Institute/Atrium Health, Charlotte, NC, USA.
Janssen (United States) · USCancer Council Queensland · AUCentre Hospitalier Universitaire de Tours · FRClinica Universidad de Navarra · ESDalhousie University · CAEmory University · USGenmab (United States) · USGold Coast Hospital · AUIcahn School of Medicine at Mount Sinai · USInstitut Català d'Oncologia · ESInstitut universitaire du cancer de Toulouse Oncopole · FRJanssen (Belgium) · BELeeds Teaching Hospitals NHS Trust · GBLevine Cancer Institute · USNagoya City University · JPNational and Kapodistrian University of Athens · GRNational Disaster Medical Center · JPPeter MacCallum Cancer Centre · AURabin Medical Center · ILRoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug Resistance, NeoplasmFemaleHumansKaplan-Meier EstimateLenalidomideMaleMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalNeoplasm, ResidualAntibodies, MonoclonaldaratumumabDexamethasoneLenalidomide

Identifiers

PMID30237262
PMCPMC6269302
OpenAlexW2890977830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.